20 January 2014
EMA/CHMP/805419/2013 **R**ev.3

Committee for Medicinal Products for Human Use (CHMP)

Agenda of January 2014 meeting

Chair: Tomas Salmonson – Vice-chair: Pierre Demolis

20 January 2014, 13:00 – 19:30, room 3A

21 January 2014, 08:30 – 19:30, room 3A

22 January 2014, 08:30 – 19:30, room 3A

23 January 2014, 08:30 – 16:00, room 3A

Declaration on conflict of interest

In accordance with the Agency's revised policy and procedure on the handling of conflicts of interests, participants in this meeting are asked to declare any conflict of interests on the matters for discussion (in particular any changes, omissions or errors to the already declared interests). Discussions, deliberations and voting will take place in full respect of the restricted involvement of Scientific Committee members and, where relevant, experts attending the plenary meeting, as announced by the Scientific Committee Secretariat at the start of meeting.

Health & Safety Information

In accordance with the Agency's Health and Safety policy, delegates are to be briefed on health & safety and emergency information and procedures prior to the start of the meeting.

Disclaimers

Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regards to therapeutic indications listed against products it must be noted that these may not reflect the full wording proposed by applicants and may also

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7418 8416
E-mail info@ema.europa.eu **Website** www.ema.europa.eu
An agency of the European Union

vary during the course of the review. The procedures discussed by the CHMP are on-going and therefore certain aspects of them are considered confidential. Additional details on some of these procedures will be published in the CHMP meeting highlights once the procedures are finalised and start of referrals will also be available. For orphan medicinal products the product name and the applicant are published as this information is already publicly available. Documents mentioned in the agenda cannot be released at present as they are currently in draft format or are classified as confidential. They will become public when adopted in their final form or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006). Of note, this agenda is a working document primarily designed for CHMP members and the work the Committee undertakes.

Further information with relevant explanatory notes can be found at the end of this document.

For adoption

AGENDA (EMA/CHMP/805419/2013) and Annex to CHMP agenda of the CHMP plenary session to be held 20-23 January 2014	
TIMESCHEDULE of the CHMP plenary session to be held 20-23 January 2014	
MINUTES (EMA/CHMP/6103/2014) of the CHMP plenary session held 16-19 December 2013	

For information

PRE-MEETING LIST of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the CHMP plenary session to be held 20-23 January 2014.	*See January 2014 Minutes (to be published post February 2014 CHMP meeting)*
Draft Agenda of 17-20 February 2014 CHMP meeting	

Table of Contents

1 ORAL EXPLANATIONS

1.1 Pre-authorisation Procedure Oral Explanations

(EMEA/H/C/002751) (umeclidinium bromide / vilanterol), (treatment to of chronic obstructive pulmonary disease (COPD)) List of Outstanding Issues adopted in November 2013, September 2013. List of Questions adopted in May 2013.	Oral explanation to be held on Tuesday 21 January 2014 at 9.00.
(EMEA/H/C/003754) (umeclidinium bromide / vilanterol) (treatment to of chronic obstructive pulmonary disease (COPD)) List of Outstanding Issues adopted in November 2013, September 2013. List of Questions adopted in May 2013.	Oral explanation to be held on Tuesday 21 January 2014 at 9.00.

Folcepri (EMEA/H/C/002570), Orphan Applicant: Endocyte Europe, B.V., (etarfolatide), (indicated for single photon emission computed tomography (SPECT) imaging) List of Outstanding Issues adopted in November 2013. List of Questions adopted in March 2013.	Possible Oral explanation
Neocepri (EMEA/H/C/002773), Orphan Applicant: Endocyte Europe, B.V., (folic acid), (indicated for the enhancement of Folcepri single photon emission computed tomography (SPECT) image quality) List of Outstanding Issues adopted in November 2013. List of Questions adopted in March 2013.	Possible Oral explanation
Vynfinit (EMEA/H/C/002571), Orphan Applicant: Endocyte Europe, B.V., (vintafolide), (treatment of platinum resistant ovarian cancer) List of Outstanding Issues adopted in November 2013. List of Questions adopted in March 2013.	Possible Oral explanation

1.2 Re-examination Procedure Oral Explanation

1.3 Post-authorisation Procedure Oral explanation

1.4 Referral Procedures Oral Explanations

Protelos (EMEA/H/A-20/1371/C/000560/0039) (Strontium Ranelate), Les Laboratoires Servier, Rapporteur: Bengt Ljungberg, Co-Rapporteur: Andrea Laslop, (treatment of osteoporosis). PRAC outcome at January 2014 PRAC meeting.	Possible Oral explanation to be held on 22 January 2014. See also 12.1 Procedure for Centrally Authorised products under Article 20 Council Regulation (EC) No 726/2004
Osseor (EMEA/H/A-20/1371/C/000561/0034) (Strontium Ranelate), Les Laboratoires Servier, Rapporteur: Bengt Ljungberg, Co-Rapporteur: Andrea Laslop, (treatment of osteoporosis). PRAC outcome at January 2014 PRAC meeting.	Possible Oral explanation to be held on 22 January 2014. See also 12.1 Procedure for Centrally Authorised products under Article 20 Council Regulation (EC) No 726/2004

2 NEW APPLICATIONS

2.1 Opinions – New full applications

Adempas (EMEA/H/C/002737), Orphan
Applicant: Bayer Pharma AG, (riociguat), (treatment of chronic thromboembolic pulmonary hypertension (CTEPH) and Pulmonary arterial hypertension (PAH))
List of Outstanding Issues adopted in November 2013.
List of Questions adopted in June 2013.

- Revised Similarity Assessment Report: **For adoption**

(EMEA/H/C/002615)
(follitropin alfa), (treatment of infertility)
List of Outstanding Issues adopted in November 2013.
List of Questions adopted in March 2013.

Cholic Acid FGK (EMEA/H/C/002081), Orphan
(CHOLIC ACID), Applicant: FGK Representative Service GmbH (treatment of inborn errors of primary bile acid synthesis),
Revised Opinion: **For adoption**

(EMEA/H/C/002735)
(albiglutide), (treatment of type 2 diabetes mellitus)
List of Outstanding Issues adopted in November 2013.
List of Questions adopted in July 2013.

(EMEA/H/W/002652)
(misoprostol), (indicated in women of childbearing age for treatment of Post Partum Haemorrhage due to uterine atony in situations where intravenous oxytocin is not available)
List of Outstanding Issues adopted in October 2013, May 2013.
List of Questions adopted in December 2012.

(EMEA/H/C/002713)
(lurasidone), (treatment of schizophrenia)
List of Outstanding Issues adopted in December 2013, July 2013.
List of Questions adopted in February 2013.

Masiviera (EMEA/H/C/002659), Orphan
Applicant: AB Science, (masitinib), (treatment of non resectable locally advanced or metastatic pancreatic cancer)
Oral explanation was held in December 2013. List of Outstanding Issues adopted in September 2013. List of Questions adopted in January 2013.

(EMEA/H/C/002546)
(laquinimod), (treatment of multiple sclerosis)
Oral explanation was held in December 2013. List of Outstanding Issues adopted in November 2013, July 2013. List of Questions adopted in November 2012.

(EMEA/H/C/003824)
(rivastigmine), (treatment of Alzheimer's dementia)

(EMEA/H/C/002817)
(serelaxin), (treatment of acute heart failure)
Oral explanation was held in December 2013. List of Outstanding Issues adopted in October 2013. List of Questions adopted in May 2013.

Translarna (EMEA/H/C/002720), Orphan
Applicant: PTC Therapeutics Limited, (ataluren), (treatment of Duchenne muscular dystrophy)
Oral explanation was held in December 2013. List of Outstanding Issues adopted in September 2013. List of Questions adopted in March 2013.

(EMEA/H/C/002805)
(zoledronic acid), (treatment of osteoporosis and Paget's disease of the bone)
List of Questions adopted in October 2013.

2.2 Day 180 List of outstanding issues – New full applications

(EMEA/H/C/002809)
(umeclidinium bromide), (treatment of symptoms in adult patients with chronic obstructive pulmonary disease)
List of Questions adopted in September 2013.

(EMEA/H/C/002603)
(hepatitis b surface antigen), (indicated for active immunisation of adults against hepatitis B virus (HBV) infection)
List of Questions adopted in December 2012.

SCENESSE (EMEA/H/C/002548), Orphan
(afamelanotide), Applicant: Clinuvel (UK) Limited, (treatment of phototoxicity in adult patients with erythropoietic protoporphyria (EPP)), List of Outstanding Issues adopted in March 2013.

(EMEA/H/C/002777)
(SIMEPREVIR), (treatment of chronic hepatitis C (CHC) genotype 1 or genotype 4 infection), List of questions adopted in September 2013.

2.3 Day 120 List of Questions – New full applications

CYRAMZA (EMEA/H/C/002829), Orphan
Applicant: Eli Lilly Nederland B.V., (ramucirumab), (treatment of gastric cancer)

(EMEA/H/C/002810)
(naloxegol), (treatment of adult patients 18 years and older with opioid-induced constipation including patients with inadequate response to laxatives)

Olaparib AstraZeneca AB
(EMEA/H/C/003726), Orphan
Applicant: AstraZeneca AB, (olaparib), (treatment of ovarian cancer)

(EMEA/H/C/003702)
(phenylephrine hydrochloride /ketorolac trometamol), (maintenance of intraoperative mydriasis, prevention of intraoperative miosis and reduction of acute postoperative ocular pain in intraocular lens replacement in adults).

SYLVANT (EMEA/H/C/003708), Orphan
Applicant: Janssen-Cilag International NV, (siltuximab), (treatment of multicentric Castleman's disease)

2.4 Update on on-going new applications for Centralised Procedures

Corluxin (EMEA/H/C/002830), Orphan,
(mifepristone), Applicant: FGK Representative Service GmbH, (treatment of signs and symptoms of endogenous Cushing's syndrome in adults)

- Assessment report of similarity: **For adoption**

KETOCONAZOLE AID-SCFM (EMEA/H/C/003800), Orphan, (ketoconazole), Applicant: Agenzia Industrie Difesa-stabilimento Chimico Farmaceutico Militare, (treatment of Cushing's syndrome)

- Timetable for the assessment of similarity: **For adoption**

Imbruvica (EMEA/H/C/003791) Orphan Applicant: Janssen-Cilag International NV, (ibrutinib), (treatment of mantle cell lymphoma, chronic lymphocytic leukaemia, small lymphocytic lymphoma)

- Assessment Report of similarity: **For adoption**

(EMEA/H/C/003843), (idelalisib), (treatment of patients with relapsed chronic lymphocytic leukaemia (CLL) and refractory indolent non-Hodgkin lymphoma (iNHL).)

- Assessment Report of similarity: **For adoption**

(EMEA/H/C/002085), (tilmanocept), (used in the delineation and localisation of lymph nodes) List of Outstanding Issues adopted in December 2013, October 2013. List of Questions adopted in May 2013.

- Letter from the applicant requesting extension of clock stop to respond to the List of Outstanding Issues adopted in December 2013 :**For discussion**

Neofordex (EMEA/H/C/002418), Orphan

(Dexamethasone Acetate), Laboratoires CTRS-Boulogne Billancourt,

- Letter from the applicant dated 13 December 2013 requesting an extension of clock stop to respond to the List of Outstanding Issues adopted in November 2013: **For information**

2.5 Products in the Decision Making Phase

3 EXTENSION OF MARKETING AUTHORISATION ACCORDING TO ANNEX I OF REG. 1234/2008

3.1 Extension of marketing authorisation according to Annex I of Reg. 1234/2008; Opinions

Mabthera (EMEA/H/C/000165/X/0083)

MAH: Roche Registration Ltd, (rituximab), Rapporteur: Jens Ersbøll, PRAC Rapporteur: Doris Stenver, "Line extension to add subcutaneous route of administration: Mabthera 1400 mg solution for subcutaneous injection."
List of Outstanding Issues adopted in November 2013.
List of Questions adopted in May 2013.

3.2 Extension of marketing authorisation according to Annex I of Reg. 1234/2008; Day 180 List of outstanding issues

3.3 Extension of marketing authorisation according to Annex I of Reg. 1234/2008; Day 120 List of Questions

Noxafil (EMEA/H/C/000610/X/0033)

MAH: Merck Sharp & Dohme Limited, (posaconazole), Rapporteur: Rafe Suvarna, PRAC Rapporteur: Julia Dunne, Line extension to Noxafil 18mg/ml concentrate for solution for infusion

3.4 Update on on-going Extension application according to Annex I of Reg. 1234/2008

Halaven (EMEA/H/C/002084/II/0011)

MAH: Eisai Europe Ltd., (eribulin), Rapporteur: Bengt Ljungberg, Co-Rapporteur: Jens Ersbøll,
This application concerns an extension of the indication of Halaven 0.44 mg/ml solution for injection to earlier lines of metastatic breast cancer . Changes have been made to SmPC sections 4.1, 4.8, and 5.1. The Package leaflet has been updated accordingly. Furthermore the product information has been updated in line with the latest version of QRD template (version 9).
Request for Supplementary Information adopted in July and December 2013.

- Letter from the MAH requesting an extension of clock stop to respond to the List of Outstanding Issues adopted in December 2013: **For information**

3.5 Extension application according to Annex I of Reg. 1234/2008- Products in the Decision Making Phase

RoActemra (EMEA/H/C/000955/X/0030)
MAH: Roche Registration Ltd, (tocilizumab), Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Agnes Gyurasics, PRAC Rapporteur: Brigitte Keller-Stanislawski, PRAC Co-Rapporteur: Julia Pallos, Extension application to register a new route of administration "subcutaneous" use, a new pharmaceutical form "solution for injection", a new strength "162 mg" and two new presentations "pre-filled pen" and "pre-filled syringe".
Positive Opinion adopted by consensus on 19 December 2013.

- Letter from the MAH dated 20 December 2013 : **For information**
- Rapporteur's and Co-Rapporteur's assessment report of the MAH's assessment and conclusions: **For information**
- Draft List of Questions to the MAH: **For adoption**

4 TYPE II VARIATIONS - Extension of indication procedures

4.1 Opinions or Requests for Supplementary information - Type II variation; Extension of indication

Arzerra (EMEA/H/C/001131/II/0023), Orphan
MAH: Glaxo Group Ltd, (ofatumumab), Rapporteur: Jens Ersbøll, Co-Rapporteur: Ingunn Hagen Westgaard, PRAC Rapporteur: Doris Stenver, "Extension of indication to the first line treatment of chronic lymphocytic leukaemia in combination with alkylator-based regimens in patients not eligible for fludarabine-based therapy. As a result, sections 2, 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2 and 6.6 of the SmPC are proposed to be updated. The Package Leaflet is updated accordingly. Editorial changes to sections 4.7 and 6.3 of the SmPC are also proposed."

Kalydeco (EMEA/H/C/002494/II/0009), Orphan

MAH: Vertex Pharmaceuticals (U.K.) Ltd., (ivacaftor), Rapporteur: Concepcion Prieto Yerro, Co-Rapporteur: Melinda Sobor, PRAC Rapporteur: Miguel-Angel Macia, "Update of sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC to extend the indication of Kalydeco in the treatment of cystic fibrosis to patients aged 6 years and older who have other gating (class III) mutation in the CFTR gene than G551D. The Package Leaflet is updated accordingly."

Nexavar (EMEA/H/C/000690/II/0035), Orphan

MAH: Bayer Pharma AG, (sorafenib), Rapporteur: Bengt Ljungberg, Co-Rapporteur: Dinah Duarte, PRAC Rapporteur: Ulla Wändel Liminga, "Extension of indication to include treatment of differentiated thyroid carcinoma. As a consequence sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC have been updated. The Package Leaflet is updated accordingly. The product information is also revised in line with QRD version 9.0. In addition the MAH took the opportunity to update the details of the local representatives and include the local representative for Croatia in the package leaflet."
Request for Supplementary Information adopted in October 2013.

NovoThirteen (EMEA/H/C/002284/II/0002)

MAH: Novo Nordisk A/S, (catridecacog), Rapporteur: Joseph Emmerich, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Evelyne Falip, "Update of section 4.1 of the SmPC to include the treatment of bleeding in children with congenital factor XIII A-subunit deficiency below 6 years of age . The package leaflet has been updated accordingly."
Request for Supplementary Information adopted in December 2013, September 2013.

Pradaxa (EMEA/H/C/000829/II/0048/G)
MAH: Boehringer Ingelheim International GmbH, (dabigatran etexilate), Rapporteur: Jens Heisterberg, Co-Rapporteur: Pierre Demolis, "Extension of indications to two new related indications:
• Treatment of acute deep vein thrombosis (DVT) and/or pulmonary embolism (PE) and prevention of related death (a VTEt)
• Prevention of recurrent deep vein thrombosis (DVT) and/or pulmonary embolism (PE) and related death (s VTEp)"
Request for Supplementary Information adopted in September 2013.

Stelara (EMEA/H/C/000958/II/0037)
MAH: Janssen-Cilag International N.V., (ustekinumab), Rapporteur: Greg Markey, Co-Rapporteur: David Lyons, PRAC Rapporteur: Julie Williams, "Extension of indication in the treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate or psoralen and ultraviolet A."

Tresiba (EMEA/H/C/002498/II/0006)
MAH: Novo Nordisk A/S, (insulin degludec), Rapporteur: Kristina Dunder, PRAC Rapporteur: Qun-Ying Yue, "Update of sections 4.2 and 5.1 of the SmPC in order to include guidance for prescribers on the use of Tresiba in combination with GLP-1 receptor agonists. The Package Leaflet was proposed to be updated accordingly.
Product Information updated in line with latest QRD template version 9 and to include some editorial changes.
The requested variation proposed amendments to the SmPC, Annex II, Labelling and Package Leaflet."

Victoza (EMEA/H/C/001026/II/0023)
MAH: Novo Nordisk A/S, (liraglutide), Rapporteur: Pieter de Graeff, "Update of the SmPC for sections 4.1, 4.2, 4.4, 4.7, 4.8 and 5.1 in order include information on the use of liraglutide in combination with basal insulin.The Package Leaflet is proposed to be updated accordingly."

Xolair (EMEA/H/C/000606/II/0048)
MAH: Novartis Europharm Ltd, (omalizumab), Rapporteur: Bengt Ljungberg, Co-Rapporteur: Arantxa Sancho-Lopez, PRAC Rapporteur: Qun-Ying Yue, "Extension of indication to include the treatment of chronic spontaneous urticaria." Request for Supplementary Information adopted in October 2013.

4.2 Update on on-going Type II variation - Extension of indications

Avastin (EMEA/H/C/000582/II/0059)

(BEVACIZUMAB), Applicant: Roche Registration Ltd, Rapporteur: Jens Ersbøll, Co-Rapporteur: Ingunn Hagen Westgaard, , Update of section 4.1 of the SmPC in order to extend the indication of Avastin in combination with radiotherapy and temozolomide for the treatment of adult patients with newly diagnosed glioblastoma. Related changes were proposed to SmPC sections 4.2, 4.5, 4.8 and 5.1. The Package Leaflet was proposed to be updated accordingly. Furthermore, the MAH took the opportunity to make some editorial changes in the SmPC and the PL". Request for Supplementary Information adopted in June and November 2013.

- Letter from the MAH dated 14 January 2013 requesting extension of clock stop to respond to the Request for Supplementary Information adopted in November 2013: **For information**

5 ANCILLARY MEDICINAL SUBSTANCES IN MEDICAL DEVICES

5.1 Opinions/ List of outstanding issues / List of Questions

(EMEA/H/D/003740)
(human serum albumin), (To scavenge embryotoxic components generated during embryo development and to facilitate embryo and gamete manipulation in IVF media)

- List of Questions: **For adoption**

(EMEA/H/D/002831)
(substance to be reviewed) insulin-like growth factor-i (igf-i) segment), (hard-to-heal wounds, primarily venous leg ulcers)

- List of Questions: **For adoption**

6 RE-EXAMINATION PROCEDURE (NEW APPLICATIONS) UNDER ARTICLE 9(2) OF REGULATION No 726/2004

Masican (EMEA/H/C/002670), Orphan
(MASITINIB), Applicant: AB Science, (treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST))New active substance (Article 8(3) of Directive No 2001/83/EC). Negative Opinion adopted in November 2013.

- Grounds for re-examination: **For information**
- Call for nomination for experts for SAG-Oncology meeting: **For information**
- Timetable: **For adoption**

7 RE-EXAMINATION PROCEDURE (TYPE II VARIATIONS) UNDER ARTICLE 6(9) OF COMMISSION REGULATION EC NO 1085/2003

8 WITHDRAWAL OF APPLICATION

Winfuran (EMEA/H/C/002683), Orphan
Applicant: Toray Europe Limited, (nalfurafine), (treatment of uraemic pruritus)
New active substance (Article 8(3) of Directive No 2001/83/EC).

- Letter from the MAH dated 17 January 2014 informing of withdrawal of the application: **For information**

9 PROCEDURE UNDER ARTICLE 83(1) OF REGULATION (EC) 726/2004 (COMPASSIONATE USE)

(compassionate use) (H0003892) (treatment of patients with hepatitis C infection that have previously failed on boceprevir or telaprevir based therapy and that are in urgent medical need for effective treatment) • Company responses to CHMP request: **For information**	

10 PRE-SUBMISSION ISSUES

Some items in this section are considered commercially confidential or sensitive and therefore not disclosed.

11 POST-AUTHORISATION ISSUES

Some items in this section are considered commercially confidential or sensitive and therefore not disclosed.

Ceplene (EMEA/H/C/000796/S/0014), Orphan (histamine dihydrochloride), Applicant: Meda AB, Rapporteur: David Lyons, PRAC Rapporteur: Almath Spooner, (treatment of myeloid leukaemia), Request for Supplementary Information adopted in March and April 2013. • Opinion: **For adoption**	Annual reassessment for product remaining under exceptional circumstances.
ellaOne (EMEA/H/C/001027/R/0025) MAH: Laboratoire HRA Pharma, SA, (ulipristal acetate), Rapporteur: Pieter de Graeff, Co-Rapporteur: Kristina Dunder, PRAC Rapporteur: Menno van der Elst, (Emergency contraception within 120 hours (5 days) of unprotected sexual intercourse or contraceptive failure), List of Outstanding Issues adopted in November and December 2013. • Opinion: **For adoption**	Renewal procedure

Vfend (EMEA/H/C/000387/II/0097) (VORICONAZOLE), Applicant: Pfizer Limited, Rapporteur: Hans Hillege, Co-Rapporteur: Pierre Demolis, Update of sections 4.1, 4.2, 4.4, 4.8 and 5.1 to include information pertaining to the proposed new indication in prophylaxis of invasive fungal infections in high risk hematopoietic stem cell transplant recipients. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity of this variation to update the SmPC, Annex II and PL in line with the latest QRD template.

- SAG anti-infectives meeting to be rescheduled: **For adoption**

---

alli (EMEA/H/C/000854/II/0042), (orlistat), MAH: Glaxo Group Ltd, Informed Consent of Xenical, Rapporteur: Rafe Suvarna, "Update to the Summary of Product Characteristics following a routine assessment of the Company Core Data sheet.
Amendment of the Product Information sections 4.3 and 4.5 to contraindicate concomitant use of non-prescription orlistat with antiretroviral medications following literature article review suggesting a possible interaction between non-prescription orlistat and efavirenz and provide information in the interaction sections.
The Product Information has also been updated to align to the revised QRD template (version 9) as part of this Type II submission and minor amendments introduced in section 4.8.
In addition, minor amendments and corrections of the local representatives are introduced."
Request for Supplementary Information adopted in October 2013, September 2013.

- PRAC recommendation for interaction between orlistat and HIV: **For discussion**
- PK WP report related to the interaction between orlistat and HIV: **For discussion**

---

12 REFERRAL PROCEDURES

12.1 Procedure for Centrally Authorised products under Article 20 Council Regulation (EC) No 726/2004

Protelos (EMEA/H/C/000560) (Strontium Ranelate), Les Laboratoires Servier, Rapporteur: Bengt Ljungberg, Co-Rapporteur: Andrea Laslop, (treatment of osteoporosis), PRAC outcome at January 2014 PRAC meeting.	Possible Oral explanation to be held on 22 January 2014. See also 1. Oral explanations
Osseor (EMEA/H/C/000561) (Strontium Ranelate), Les Laboratoires Servier, Rapporteur: Bengt Ljungberg, Co-Rapporteur: Andrea Laslop, (treatment of osteoporosis), PRAC outcome at January 2014 PRAC meeting.	Possible Oral explanation to be held on 22 January 2014. See also 1. Oral explanations

12.2 Requests for CHMP Opinion under Article 5(3) and 57 (1)p of Regulation (EC) No 726/2004

12.3 Procedure under Articles 5(2) and 10 of the Regulation (EC) No 726/2004

12.4 Disagreement between Member States on application for medicinal product (Potential serious risk to Public Health) –under Article 29(4) of Directive 2001/83/EC

12.5 Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC

Rocephin (EMEA/H/A-30/1302)
(ceftriaxone), Roche group of companies, Rapporteur: Greg Markey, Co-Rapporteur: Juris Pokrotnieks,
Rocephin is indicated for the treatment of the infections in adults and children including neonates (from birth) (antibiotic).
List of Outstanding Issues was adopted in July 2012 May and October 2013.

- Opinion: **For adoption**

Article 30 list for SmPC harmonisation to be triggered by the EC in 2014: For adoption

Call for expression of interest in Rapporteurship: **For discussion**

Letter from CMDh to EC dated 15 January 2014 seeking agreement on the proposed list: **For information**
List of products identified by CMDh: **For information**
Agreement letter from the EC dated 2014: **For information**
Proposed timelines to trigger the referrals: **For adoption**

List of products:
Haldol (haloperidol), Janssen-Cilag

Cymevene (ganciclovir), F. Hoffmann-La Roche

Novantrone (mitoxantrone) Meda Pharma

12.6 Community Interests - Referral under Article 31 of Directive 2001/83/EC

Emergency contraceptives (EMEA/H/A-31/1391)

NAPs: **emergency contraceptive medicinal products containing levonogestrel and ulipristal**

CAP: **ellaOne** (ulipristal acetate), MAH: Laboratoire HRA Pharma, SA

Influence of body weight and Body mass index (BMI) of women on the efficacy of the emergency contraceptives.

- Letter from the Medical Products Agency in Sweden dated 16 January 2014 notifying of official referral under Article 31 and its grounds: **For information**
- Appointment of (Co)Rapporteur: **For discussion**
- List of Questions: **For adoption**
- Timetable: **For adoption**

Agents acting on the renin-angiotensin system (CAP, NAP) (EMEA/H/A-31/1370)
angiotensin receptor blockers (ARBs), angiotensin converting enzyme inhibitors (ACEi), direct renin inhibitors (aliskiren)

Review of the risks of dual blockade of the renin angiotensin system through concomitant use of ARBs, ACEi or aliskiren-containing medicines following notification by Italy of a referral under Article 31 of Directive 2001/83/EC based on pharmacovigilance data
PRAC Rapporteur: Carmela Macchiarulo, PRAC Co-Rapporteurs: Margarida Guimarães, Valerie Strassmann, Tatiana Magálová, Dolores Montero Corominas, Almath Spooner, Menno van der Elst, Julie Williams, Qun-Ying Yue,

- Revised List of Questions to the SAG CVS : **For adoption**
- List of experts for the SAG CVS : **For adoption**
- Letter to MAHs regarding participation to the SAG CVS meeting : **For information**

12.7 Re-examination Procedure under Article 32(4) of Directive 2001/83/EC

Estradiol (topical use) (EMEA/H/A-31/1336)
Rapporteur: Martina Weise, Co-Rapporteur: Hubert Leufkens,

Review of the benefit-risk balance of medicinal products containing estradiol for intravaginal administration and administration on the skin of the vulva due to observed high systemic absorption which may lead to safety issues.

- Letter from Dr August Wolff GmbH &Co KG Arzneilmittel dated 3 January 2014 requesting a re-examination of Opinion adopted in December 2013: **For information**
- Appointment of Re-examination (Co)Rapporteurs: **For discussion**

12.8 Procedure under Article 107(2) of Directive 2001/83/EC

12.9 Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) (EC) No 1084/2003)

12.10 Procedure under Article 29 Regulation (EC) 1901/2006

Crestor and associated names (EMEA/H/A-29/1378)
MAH: AstraZeneca, (rosuvastatin), Rapporteur: Pieter de Graeff, Co-Rapporteur: Radka Montoniová, Application to extend the age range of the existing paediatric indication [hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type IIb) as an adjunct to diet when response to diet and other non-pharmacological treatments is inadequate] from patients aged 10 to 17 to patients aged 6 to 17 years.

- List of Questions: **For adoption**

12.11 Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) No 1234/2008)

13 PHARMACOVIGILANCE ISSUES

Summary of recommendations and advice of PRAC meeting held on 6-9 January 2014: **For information**

List of Union Reference Dates and frequency of submission of Periodic Safety Update Reports (EURD list) for January 2014: **For adoption**

Early Notification System:
January 2014 Early Notification System on Envisaged CHMP Recommendations for Regulatory Action (based on Identified Safety Concerns) Accompanied by Communication to the General Public: **For information**

NeoRecormon (EMEA/H/C/000116) MEA 052.1 (Epoetin Beta), Roche Registration Ltd, Rapporteur: Martina Weise, Co-Rapporteur: Pierre Demolis, PRAC Rapporteur: Valerie Strassmann, Evaluation of interim PASS results • PRAC updated Assessment Report: **For discussion**	

14 INSPECTIONS

14.1 GMP Inspections

Request for GMP Inspections: **For adoption**	*Disclosure of information related to GMP inspections will not be published as it undermines the purpose of such inspections.*

14.2 GCP Inspections

Request for GMP Inspections: **For adoption**	*Disclosure of information related to GCP inspections will not be published as it undermines the purpose of such inspections.*

14.3 Pharmacovigilance Inspections

Request for Pharmacovigilance Inspections: **For adoption**	*Disclosure of information related to Pharmacovigilance inspections will not be published as it undermines the purpose of such inspections.*

14.4 GLP Inspections

Request for GLP Inspections: **For adoption**	*Disclosure of information related to GLP inspections will not be published as it undermines the purpose of such inspections.*

15 INNOVATION TASK FORCE

15.1 Minutes of ITF: For information

15.2 Briefing meetings (Innovation Task Force)

Disclosure of information related to briefing meetings taking place with applicants cannot be released at present time as deemed to contain commercially confidential information.

15.3 Eligibility to EMA scientific services

15.4 Requests for CHMP Opinion under Article 57 (1)P of Regulation (EC) NO 726/2004

15.5 Nanomedicines activities

16 SCIENTIFIC ADVICE WORKING PARTY (SAWP)

Report from the SAWP meeting held on 7-9 January 2014. Table of conclusions: **For information**	
Scientific advice letters:	*Disclosure of information related to scientific advice letters cannot be released at present time as these contain commercially confidential information.*

17 SATELLITE GROUPS

17.1 Coordination Group for Mutual Recognition and Decentralised Procedures

Report from the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) on the meeting held on 20-22 January 2014: **For information**	

18 OTHER COMMITTEES

18.1 Committee for Orphan Medicinal Products (COMP)

Press release of the COMP meeting held on 7-8 January 2014: **For information**	To be sent in the Post-mail.

18.2 Committee for Herbal Medicinal Products (HMPC)

Report from the HMPC meeting held on 11-12 November 2013: **For information**	To be sent in the Post-mail.

18.3 Paediatric Committee (PDCO)

PIPs reaching D30 at January 2014 PDCO: **For**	To be sent in the Post-mail.

information
Report from the PDCO meeting held on 15-17 January 2014: **For information**

18.4 Committee for Advanced Therapies (CAT)

Table of Decisions of CAT meeting held on 16-17 January 2014: **For information**

19 INVENTED NAME ISSUES

20 ANY OTHER BUSINESS

Expertise identification of Co-opted Member: **For discussion**	Election of CHMP Co-opted member at the February 2014 CHMP meeting. In view of the 3-year mandate expiring for Robert Hemmings, the CHMP is asked to review the current areas of its expertise and agree at this meeting on the additional expertise that might be required.
Explanatory note on the withdrawal of the note for guidance on harmonisation of requirements for influenza Vaccines (CPMP/BWP/214/96) and of the core SmPC/PL for inactivated seasonal influenza vaccines (CMDh/128/2003/Rev5 and CMDh/129/2008/Rev3) following end of public consultation on 31 October and comments from stakeholders: **For adoption**	
Proposal for a framework to incorporate patients' views during evaluation of benefit-risk by the EMA Scientific Committees: **For discussion**	
Follow up actions on Minutes of the CHMP Informal meeting held in Vilnius (29-30 October 2013): **For discussion** • Topics identified for follow-up • Topic leaders	
Presentation on the Move to Churchill Place: **For information**	

Cardiovascular Working Party Work Programme for 2014: **For adoption**
Cardiovascular Working Party • Wording of indication for medicinal products for treatment of type 2 diabetes: **for discussion**
Pharmacogonomics Working Party Work Programme for 2014: **For adoption**
Pharmacokinetics Working Party Work Programme for 2014: **For adoption**
Gastroenterology Drafting Group Work Programme for 2014: **For adoption**
Rheumatology-Immunology Working Party Work Programme for 2014: **For adoption**
Urology Drafting Group: **For discussion**
Response from the RIWP to the CMDh letter from regarding interpretation of the Guideline on Clinical Investigation of Medical Products Used in the Treatment of Osteoarthritis (CPMP/EWP/784/97 Rev.1): **For adoption**
General discussion on combination packs - Follow up from ITF reports at December 2013 Plenary • Briefing note: **For discussion** • Two ITF reports adopted in December: **For information**
Q&A on Benzyl alcohol (EMA/508188/2013): **For adoption for 3-month public consultation**
Q&A on Benzoic acid (EMA/508189/2013): **For adoption for 3-month public consultation**
Q&A on Ethanol (EMA/507988/2013)**: For adoption for 3-month public consultation**

Update from CHMP sub-group on supply shortages: **For information** • Presentation: **For information** • CHMP briefing note: **For information** • Work programme 2014-2015: **For adoption**	CHMP sub-group and HMA virtual group on supply shortages – presentation on groups' work and introduction of the work programme for 2014-2015
Guideline on the investigation of subgroups in confirmatory clinical trials (Biostatistics Working Party): **For adoption for a 6-month public consultation**	
Proposal to change to the Geriatric Expert Group (GEG) mandate (from 12 to 13 core members) • Revised GEG Mandate, objectives and rules: **For adoption** • Geriatric Expert Group Nominees: **For adoption**	
Reflection paper on Orphan Similarity assessment: **For discussion and adoption**	
Planned list of Workshop across Working Parties: **For discussion**	

Explanatory notes

The notes below give a brief explanation of the main sections and headings in the CHMP agenda and should be read in conjunction with the agenda or the minutes.

Oral explanations *(section 1)*

The items listed in this section are those for which marketing authorisation holders (MAHs) or applicants have been invited to the CHMP plenary meeting to address questions raised by the Committee. Oral explanations normally relate to on-going applications (section 2 and 3) or referral procedures (section 12) but can relate to any other issue for which the CHMP would like to discuss with company representatives in person.

New applications *(section 2)*

This section lists applications for marketing authorisations of new medicines that are to be discussed by the Committee.

Section 2.1 is for medicinal products nearing the end of the evaluation and for which the CHMP is expected to adopt an **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CHMP. The clock stop happens after day 120 and may also happen after day 180, when the CHMP has adopted a list of questions or outstanding issues to be addressed by the company. Related discussions are listed in the agenda under sections 2.2 (**Day 180 List of outstanding issues**) and 2.3 (**Day 120 list of questions**).

CHMP discussions may also occur at any other stage of the evaluation, and these are listed under section 2.4, **update on ongoing new applications for centralised procedures**.

The assessment leads to an opinion from the CHMP by day 210. Following a CHMP opinion the European Commission takes usually 67 days to issue a legally binding decision (i.e. by day 277 of the procedure). CHMP discussions on products that have received a CHMP opinion and are awaiting a decision are listed under section 2.5, **products in the decision making phase**.

Extension of marketing authorisations according to Annex I of Reg. 1234/2008 *(section 3)*

Extensions of marketing authorisations are applications for the change or addition of new strengths, formulations or routes of administration to existing marketing authorisations. Extension applications follow a 210-day evaluation process, similarly to applications for new medicines (see figure above).

Type II variations - Extension of indication procedures *(section 4)*

Type II variations are applications for a change to the marketing authorisation which requires an update of the product information and which is not covered in section 3. Type II variations include applications for a new use of the medicine (extension of indication), for which the assessment takes up to 90 days. For the applications listed in this section, the CHMP may adopt an opinion or request supplementary information from the applicant.

Ancillary medicinal substances in medical devices *(section 5)*

Although the EMA does not regulate medical devices it can be asked by the relevant authorities (the so-called Notified Bodies) that are responsible for regulating these devices to give a scientific opinion on a medicinal substance contained in a medical device.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 *(section 6)*

This section lists applications for new marketing authorisation for which the applicant has requested a re-examination of the opinion previously issued by the CHMP.

Re-examination procedures *(section 7)*

This section lists applications for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP.

Withdrawal of application *(section 8)*

Applicants may decide to withdraw applications at any stage during the assessment and a CHMP opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

Procedure under article 83(1) of regulation (EC) 726/2004 (compassionate use) *(section 9)*

Compassionate use is a way of making available to patients with an unmet medical need a promising medicine which has not yet been authorised (licensed) for their condition. Upon request, the CHMP provides recommendations to all EU Member States on how to administer, distribute and use certain medicines for compassionate use.

Pre-submission issues *(section 10)*

In some cases the CHMP may discuss a medicine before a formal application for marketing authorisation is submitted. These cases generally refer to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation. In case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

Post-authorisation issues *(section 11)*

This section lists other issues concerning authorised medicines that are not covered elsewhere in the agenda. Issues include supply shortages, quality defects, some annual reassessments or renewals or type II variations to marketing authorisations that would require specific discussion at the plenary.

Referral procedures *(section 12)*

This section lists referrals that are ongoing or due to be started at the plenary meeting. A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the EU. Further information on such procedures can be found here.

Pharmacovigilance issues *(section 13)*

This section lists issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines. Feedback is provided by the PRAC. This section also refers to the early notification system, a system used to notify the European regulatory network on proposed EMA communication on safety of medicines.

Inspections Issues *(section 14)*

This section lists inspections that are undertaken for some medicinal products. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Innovation task force *(section 15)*

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes from the last ITF meeting as well as any related issue that requires discussion with the CHMP are listed in this section of the agenda. Further information on the ITF can be found here.

Scientific advice working party (SAWP) *(section 16)*

This section refers to the monthly report from the CHMP's Scientific Advice Working Party (SAWP) on scientific advice given to companies during the development of medicines. Further general information on SAWP can be found here.

Satellite groups / other committees *(section 17)*

This section refers to the reports from groups and committees making decisions relating to human medicines: the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh), the Committee for Orphan Medicinal Products (COMP), the Committee for Herbal Medicinal Products (HMPC), Paediatric Committee (PDCO), the Committee for Advanced Therapies (CAT) and the Pharmamacovigilance Risk Assessment Committee (PRAC).

Invented name issues *(section 18)*

This section list issues related to invented names proposed by applicants for new medicines. The CHMP has established the Name Review Group (NRG) to perform reviews of the invented names. The group's main role is to consider whether the proposed names could create a public-health concern or potential safety risk. Further information can be found here.